June 1, 2021
Praetego Inc, a preclinical stage pharmaceutical company developing novel candidates against chronic diseases of aging, is pleased to announce an award of a $458K grant to study the Amadorin candidates for the treatment of Alzheimer’s Disease. Funded jointly between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Aging (NIA) of the National Institutes of Health, the award expands the preclinical characterization of Praetego’s lead candidates.
